StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Tradipitant

HCID 9916461
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
622370-35-8
Standard-SMILES
O=C(c1ccccc1Cl)c1cccnc1-c1nnn(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c1-c1ccncc1
InChIKey
CAVRKWRKTNINFF-UHFFFAOYSA-N
Summenformel
C28H16ClF6N5O
Durchschnittliche Molmasse
587,9 g/mol
Monoisotopische Masse
587,0947568

Überblick

Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. NK-1 receptors are expressed in the brainstem and nucleus tractus solitarius, which receives emetogenic signals from various stimuli including dizziness and vertigo. Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.

Namen und Bezeichner

Bevorzugter Name
Tradipitant
IUPAC
[2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]-3-pyridinyl]-(2-chlorophenyl)methanone
Englischer Name
Tradipitant
Summenformel
C28H16ClF6N5O
Molmasse
587.9

Namen und Synonyme

Tradipitant622370-35-8LY686017LY-686017VLY-686NY0COC51FI[2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanoneDTXSID801045805Methanone, (2-(1-((3,5-bis(trifluoromethyl)phenyl)methyl)-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl)-3-pyridinyl)(2-chlorophenyl)-tradipitantum(2-(1-((3,5-bis(trifluoromethyl)phenyl)methyl)-5-pyridin-4-yltriazol-4-yl)pyridin-3-yl)-(2-chlorophenyl)methanoneMethanone, [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)-
Weitere Namen anzeigen
(2-bromopyridin-3-yl)(2-chlorophenyl)methanoneVLY 686BiafunginTradipitant APITradipitant(VLY-686)Tradipitant, 10 mM in DMSOtradipitant,VLY-686, LY686017
RefChem:933246DTXCID6015277342-(1-((3,5-bis(trifluoromethyl)phenyl)methyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)-3-(2-chlorobenzoyl)pyridine(2-(1-(3,5-bis(trifluoromethyl)benzyl)-5-(pyridin-4-yl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)(2-chlorophenyl)methanoneMFCD28127604[2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-(4-pyridinyl)-1H-1,2,3-triazol-4-yl]-3-pyridinyl](2-chlorophenyl)MethanoneVLY686UNII-NY0COC51FI

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
6,2
Polarare Oberfläche (TPSA)
73,6 Ų
H-Brücken-Donoren
0
H-Brücken-Akzeptoren
11
Frei drehbare Bindungen
6
Schwere Atome
41
Formalladung
0
Komplexität
865

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Antiemetics; Neurokinin-1 Receptor Antagonists

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
143 · 143 - 145°C
Siedepunkt
640.9 · 640.9±65.0 °C(Predicted)
Dichte
1.45 · 1.45±0.1 g/cm3(Predicted)
storage temp.
-20 °C · Hygroscopic, -20°C Freezer, Under inert atmosphere
Löslichkeit
Chloroform (Slightly), Ethyl Acetate (Slightly)
Aggregatzustand
Solid
pka
2.92 · 2.92±0.10(Predicted)
Farbe
Pale Beige to Brown
InChIKey

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302

Chemie und Industrie

Pharmakologische Informationen

Protein BindingTradipitant plasma protein binding ranged from 96% to >99% in vitro.
Pharmacodynamics · 1 Eintrag

Tradipitant inhibits the NK-1 receptor with a Ki of 0.062 nM and effectively blocks Substance P-induced intracellular calcium mobilization. The drug crosses the blood-brain barrier and achieves high receptor occupancy; a clinical study demonstrated that tradipitant occupies approximately 93% of NK-1 receptors in the frontal cortex following multiple doses. In clinical trials involving preventing vomiting induced by motion, single oral doses of 85 mg and 170 mg demonstrated significant efficacy in reducing vomiting incidence compared to placebo, with effects observed in variable sea conditions. At the maximum recommended single dose of 170 mg, tradipitant does not cause clinically significant prolongation of the QTc interval.

Mechanism of Action · 1 Eintrag

Tradipitant is a selective, high-affinity antagonist of the human substance P/neurokinin-1 (NK-1) receptor. NK-1 receptors are widely distributed in the central nervous system, particularly in brainstem nuclei such as the nucleus tractus solitarius (NTS) and the area postrema, which play a critical role in the regulation of vomiting, as well as in the peripheral gastrointestinal tract. Tradipitant works by blocking the binding of Substance P, the endogenous ligand, to NK-1 receptors, thereby inhibiting the transmission of emetogenic sensory signals from vestibular and visceral sources to the vomiting center. Unlike some other anti-emetics, tradipitant does not exhibit affinity for serotonin (5-HT3), dopamine (D2), cholinergic, or histamine (H1) receptors.

Biological Half-LifeThe observed mean elimination half-life for tradipitant is approximately 34 hours.
Metabolism/Metabolites · 1 Eintrag

Tradipitant is extensively metabolized; however, the metabolic pathways have not been fully characterized. In vitro findings suggest that non-CYP450-mediated processes and CYP enzymes (CYP3A4, CYP2C19, and to a lesser extent by CYP2C8) are involved in the metabolism of tradipitant. Tradipitant is also glucuronidated by UGT1A4 and UGT2B7. Four major metabolites (M2, M3, M4, and M8) were identified in plasma. Following a single dose of 85 mg tradipitant in healthy subjects under fasting conditions, the AUCs of M2, M3, M4, and M8 represent 40%, 33%, 43%, and 42% of the parent AUC, respectively. The major metabolites of tradipitant (M2, M3, M4, and M8) exhibited NK-1 receptor binding affinities comparable to those of the parent drug.

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 130680
HRID 130680als Produkt
Reaktionsgleichung von HRID 130681
HRID 130681als Produkt
Reaktionsgleichung von HRID 1620793
HRID 1620793als Produkt
Reaktionsgleichung von HRID 2251994
HRID 2251994als Edukt
Reaktionsgleichung von HRID 2251999
HRID 2251999als Produkt
Reaktionsgleichung von HRID 2325569
HRID 2325569als Edukt
Reaktionsgleichung von HRID 2336080
HRID 2336080als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
622370-35-8
PubChem CID
9916461
DTXSID
DTXSID801045805
ChEMBL
CHEMBL3544984
UNII
NY0COC51FI
Nikkaji
J3.048.437A
CAVRKWRKTNINFF-UHFFFAOYSA-N
SMILES
C(C1=CC=CN=C1C1=C(C2C=CN=CC=2)N(CC2=CC(C(F)(F)F)=CC(C(F)(F)F)=C2)N=N1)(C1=CC=CC=C1Cl)=O
Absorption, Distribution and Excretion · 4 Einträge

Absolute oral bioavailability has not been studied in humans. Following a single dose of 85 mg tradipitant in healthy subjects under fasting conditions, tradipitant geometric mean Cmax was 84.7 ng/mL, AUC0-inf was 1839 ng x h/mL, and the median Tmax was 2.0 hours. Following a single dose of 170 mg tradipitant in healthy subjects under fasting conditions, tradipitant geometric mean Cmax was 112 ng/mL, AUC0-inf was 3,526 ng x h/mL, and the median Tmax was 1.50 hours. In healthy subjects, a high-fat meal increased AUC0-inf and Cmax, while delaying Tmax.

Following a single oral dose of radiolabeled tradipitant 25 mg, approximately 88% of the dose was recovered, with 80% of the dose in feces and 7% in urine. Unchanged tradipitant was minimal in feces and was not detected in urine.

The apparent volume of distribution (Vd/F) of tradipitant is 1956 L in healthy subjects.

The apparent oral clearance of tradipitant is 41.7 L/hour in healthy subjects.

Anwendungen

VerwendenTradipitant, is a neurokinin-1 (NK-1) antagonist.